BR112019000636A2 - formas de dosagem de liberação prolongada de pregabalina - Google Patents

formas de dosagem de liberação prolongada de pregabalina

Info

Publication number
BR112019000636A2
BR112019000636A2 BR112019000636-2A BR112019000636A BR112019000636A2 BR 112019000636 A2 BR112019000636 A2 BR 112019000636A2 BR 112019000636 A BR112019000636 A BR 112019000636A BR 112019000636 A2 BR112019000636 A2 BR 112019000636A2
Authority
BR
Brazil
Prior art keywords
pregabalin
release
hours
pharmaceutical compositions
prolonged release
Prior art date
Application number
BR112019000636-2A
Other languages
English (en)
Inventor
Sela Yoram
Rubnov Shai
Original Assignee
Mapi Pharma Ltd.
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd., Jiangsu Nhwa Pharmaceutical Co., Ltd. filed Critical Mapi Pharma Ltd.
Publication of BR112019000636A2 publication Critical patent/BR112019000636A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C1/00Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção se refere a composições farmacêuticas de liberação prolongada compreendendo pregabalina ou um sal do mesmo, que são adaptados à liberação do ingrediente ativo pregabalina de acordo com um perfil de liberação duplo. as formulações compreendem dois componentes, o primeiro (er rápida) fornecendo liberação prolongada do ingrediente ativo em um modo controlado curto durante de cerca de 4 a cerca de 6 horas, e o segundo (er lenta ou de manutenção) fornecendo a liberação prolongada do ingrediente ativo durante um período de 24 horas. a proporção de cada componente na formulação pode ser ajustada para conseguir a auc e o efeito terapêutico desejado após a administração oral a um sujeito. a invenção ainda se refere aos métodos de uso de composições farmacêuticas para o tratamento de condições e distúrbios que respondem ao tratamento com pregabalina, tais como dor neuropática associada com neuropatia diabética periférica (dpn), neuralgia pós-herpética (phn), epilepsia, convulsões e fibromialgia.
BR112019000636-2A 2016-07-17 2017-07-16 formas de dosagem de liberação prolongada de pregabalina BR112019000636A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363267P 2016-07-17 2016-07-17
US62/363,267 2016-07-17
PCT/IL2017/050802 WO2018015946A1 (en) 2016-07-17 2017-07-16 Extended release dosage forms of pregabalin

Publications (1)

Publication Number Publication Date
BR112019000636A2 true BR112019000636A2 (pt) 2019-04-30

Family

ID=60992289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000636-2A BR112019000636A2 (pt) 2016-07-17 2017-07-16 formas de dosagem de liberação prolongada de pregabalina

Country Status (8)

Country Link
US (2) US11026908B2 (pt)
EP (1) EP3484456A4 (pt)
CN (1) CN109475510B (pt)
AU (1) AU2017300185B2 (pt)
BR (1) BR112019000636A2 (pt)
CA (1) CA3030105A1 (pt)
IL (1) IL263941B (pt)
WO (1) WO2018015946A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018015946A1 (en) * 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
WO2019238068A1 (zh) * 2018-06-13 2019-12-19 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CA3105212A1 (en) * 2018-06-28 2020-01-02 Mylan Inc. Pregabalin extended-release formulations
WO2021181262A1 (en) * 2020-03-09 2021-09-16 Almendro Properties And Trading Llp Controlled release formulations comprising drotaverine or salt thereof
MX2022015331A (es) 2020-12-04 2023-02-01 Laboratorios Silanes S A De C V Composicion farmaceutica solida recubierta y estable de un analgesico opioide y un antiepileptico para el dolor.
WO2022256545A1 (en) * 2021-06-04 2022-12-08 Nevakar Injectables Inc. Injectable pregabalin formulations
CN114983951B (zh) * 2021-12-24 2023-11-07 微研优仿医药科技(江苏)有限公司 一种胃漂浮片组合物及其制备方法
CN116850153B (zh) * 2023-06-12 2024-02-06 则正(上海)生物科技有限公司 一种普瑞巴林药物组合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898736A (en) * 1988-03-09 1990-02-06 Merck & Co., Inc. Method for tablet preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
WO2001007037A1 (en) 1999-07-22 2001-02-01 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
CA2363902C (en) 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
EP1677757A2 (en) 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption
US20060159233A1 (en) * 2005-01-19 2006-07-20 Cotton John M Re-arrangeable analog electrical cross connect
BRPI0614021A2 (pt) 2005-01-21 2011-03-01 Pharmanova Inc formulações farmacêuticas e métodos de uso
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
CN1857244A (zh) 2006-03-06 2006-11-08 重庆医药工业研究院有限责任公司 普瑞巴林缓释药物组合物
JP2011504491A (ja) * 2007-11-23 2011-02-10 ルピン・リミテッド プレガバリンの制御放出医薬組成物
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
CN102548544B (zh) 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
KR101317592B1 (ko) 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
KR101648490B1 (ko) 2009-11-02 2016-08-17 한미사이언스 주식회사 위체류 약물 전달시스템을 이용한 서방성 경구용 제제
EP2615913A4 (en) * 2010-09-17 2014-03-19 Panacea Biotec Ltd EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
ES2586057T3 (es) * 2011-07-26 2016-10-11 Yuhan Corporation Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases
US10561602B2 (en) * 2015-05-26 2020-02-18 Isa Odidi Controlled extended release pregabalin
WO2018015946A1 (en) * 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin

Also Published As

Publication number Publication date
US20190298675A1 (en) 2019-10-03
IL263941B (en) 2022-01-01
EP3484456A1 (en) 2019-05-22
US11026908B2 (en) 2021-06-08
CN109475510B (zh) 2023-03-10
WO2018015946A1 (en) 2018-01-25
EP3484456A4 (en) 2020-03-18
AU2017300185A1 (en) 2019-01-24
US20210260006A1 (en) 2021-08-26
IL263941A (en) 2019-02-28
AU2017300185B2 (en) 2023-02-02
CA3030105A1 (en) 2018-01-25
CN109475510A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
BR112019000636A2 (pt) formas de dosagem de liberação prolongada de pregabalina
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
WO2016134291A3 (en) Mixed allergen compositions and methods for using the same
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
EA201791067A1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
DOP2024000099A (es) Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CO2021000450A2 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: MAPI PHARMA LTD. (IL)